Home News Company News
Influenza: are we ready?


As WHO mentioned in the Influenza Transmission Zones , increasing activity in some areas of the temperate southern hemisphere has been reported, although influenza activity continued to decrease following a peak in March 2022.

  • Influenza detections continued to increase in Southern Africa with the majority of detections reported as influenza A(H1N1)pdm09, followed by some influenza A(H3N2) and very few influenza B viruses.
  • In East Asia, influenza activity of predominantly influenza A(H3N2) and influenza-like illness(ILI) activity increased in the southern provinces of China. Respiratory illness indicators remained elevated in Mongolia, though influenza detections were low. Elsewhere, influenza illness indicators and activity remained low.
  • The WHO GISRS laboratories tested more than 161,959 specimens during 30 May 2022 to 12 June 2022. 9069 were positive for influenza viruses, of which 8839(97.5%) were typed as influenza A and 230 (2.5% as influenza B. Of the sub-typed influenza A viruses, 97 (2.3%) were influenza A (H1N1)pdm09 and 4203 (97.7%) were influenza A (H3N2). Of the characterized B viruses, 3 (6.5%) belonged to the B-Yamagata lineage and 43 (93.5%) to the B-Victoria lineage.

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary from October 3, 2021 to June 25, 2022 were shown as bellowed:

Within 8 months, the flu positive specimens increased from 0.53% to 2.74%;

The flu A ratio increased from 98.4% to 99.5%, among which, the subtype of H3N2 occupied 99.9%, and the H1N1 occupied 0.1%;

The flu B ratio deceased from 1.6% to 0.5%;


As one of the global suppliers of in vitro diagnostics core raw materials and solutions, Fapon Biotech is committed to assisting global IVD partners to promote the development and launch of Influenza-related and COVID-FLU-related combo detection products in Rapid Test. The COVID-19-FLU A- FLU B Combo detection raw materials is launched to help the efficient on-site identification of SARS-CoV-2 and influenza A/B virus infection and control the input and spread of the virus at the first time.

As shown in the picture, the influenza raw materials from Fapon Biotech have an excellent sensitivity. For the specificity, 156 nasal and throat swab samples were tested respectively. There is no false positive(0/156occurs With blocker HIER-M-004.

- No cross reaction between influenza A and B.

- 156 nasal and throat swab samples were tested respectively. There is no false positive(0/156occurs With blocker HIER-M-004.

The best way to reduce your risk from seasonal flu and its potentially serious complications is to get vaccinated every year.


Besides the influenza pandemic, during the COVID-19 pandemic, WHO encourages countries, to conduct integrated surveillance of influenza and SARS-CoV-2 and report epidemiological and laboratory information in a timely manner to established regional and platforms.


The symptoms of people infected by the COVID-19 and influenza are the same as other respiratory infections. Therefore, when these patients have some corresponding symptoms, it is particularly important to diagnose these patients quickly and accurately. The combo detection method can point the direction for the patient's next treatment and isolation.


Product superiority

For flu:

  • Validated by the NIBSC & newly released China CDC influenza panels;
  • Excellent sensitivity & specificity
  • No cross-reaction to other respiratory diseases

For COVID-19:

  • High sensitivity, Low detection limit;
  • No cross-reaction to other respiratory diseases

For combo:

  • No cross-reaction to each other and other respiratory diseases
  • Variety of pairing options
  • With the combo, the performance of each item is not affected


Want more information from Fapon?

FAPON: your EMPOWERING partner of timely, accurate and affordable diagnosis solutions!